Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

[1]  Stephane Chauvie,et al.  International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers , 2013, The Journal of Nuclear Medicine.

[2]  R. Advani,et al.  Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Scott E Smith,et al.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Amthauer,et al.  Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial , 2012, The Lancet.

[5]  C. Poirot,et al.  Management of fertility in patients treated for Hodgkin’s lymphoma , 2011, Haematologica.

[6]  A. Rossi,et al.  ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. , 2011, The New England journal of medicine.

[7]  J. Radford,et al.  Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  A. Pettitt,et al.  Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. Angrilli,et al.  ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Advani,et al.  Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  F. d'Amore,et al.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Rowe,et al.  Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. , 2007, Blood.

[14]  P. Gobbi,et al.  ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Habermann,et al.  Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Connors,et al.  State-of-the-art therapeutics: Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Niedzwiecki,et al.  How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Connors,et al.  Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Dirk Hasenclever,et al.  Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial , 2002, The Lancet.

[20]  D. Winfield,et al.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.

[21]  J. Smith,et al.  Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. , 1972, Annals of internal medicine.